ICE REGIMEN IN ADULT ADVANCED/RELAPSED SOFT TISSUE SARCOMA PATIENTS; IS IT MORE EFFECTIVE IN EARLY USE? RETROSPECTIVE ANALYSIS OF SINGLE CENTER STUDY

ZEYNEP ORUC, YASİN SEZGİN, OGUR KARHAN, SENAR EBİNC, MUHAMMET ALİ KAPLAN, MEHMET KUCUKONER, ZUHAT URAKCİ, IDRİS ORUC, ABDURRAHMAN ISİKDOGAN

Eurasian Journal of Medical Investigation - 2021;5(2):274-282

Objectives: To analyze the efficacy and tolerability of the ICE regimen and prognostic factors for survival in patients with advanced or relapsed soft tissue sarcomas treated with the ICE regimen (ifosfamide, carboplatin and etoposide). Methods: The records of 28 patients diagnosed with advanced or relapsed soft tissue sarcoma who were treated with the ICE regimen at our center between 2008 and 2020, were evaluated retrospectively. Results: The most common histopathological subtype were pleomorphic sarcoma (9/32.1%). After a median follow-up duration of 8 months, the median PFS and OS were 6 months (95% confidence interval (CI), 3.6–8.3) and 9.3 months (95% CI, 4.7–13.9), respectively. A multivariate analysis for overall survival revealed the ICE treatment line (HR:4.8, 95% Cl 1.7–12.8, p: 0.002), tumor site (HR: 0.12, 95% Cl 0.03–0.4, p: 0.001) and response to ICE regimen (HR: 0.09, 95% Cl 0.01–0.49, p: 0.005) to be independent prognostic factors. The group that received 1–2 chemotherapy regimens prior to the ICE regimen recorded better OS than the group received more than two chemotherapy regimens (22.8 months vs 5 months, p: 0.006). Conclusion: The ICE regimen may be particularly effective when used for early treatment after doxorubicin-based therapy in patients with advanced or relapsed soft tissue sarcomas.